Here are the 10-K annual reports from Protalix BioTherapeutics, Inc. (PLX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLX filings page.
Protalix BioTherapeutics is a commercial-stage biopharmaceutical company focused on rare diseases using its proprietary plant cell-based protein expression platform, ProCellEx. The company markets two enzyme replacement therapies: Elelyso for Gaucher disease and Elfabrio for Fabry disease, both manufactured on this platform.
Elelyso is supplied to Pfizer globally (excluding Brazil) and to Fiocruz in Brazil, with revenues recognized on drug substance deliveries that may be uneven due to bulk ordering patterns. Elfabrio is commercialized worldwide by Chiesi, which purchases finished product from Protalix and manages all patient-facing commercial activities.
The filing highlights 2025 developments, including inclusion in the Russell 3000 and 2000 Indexes, a CFO transition, and the European Commission approval of a 2 mg/kg every-four-weeks Elfabrio dosing regimen for stable adult Fabry patients after a successful appeal. Protalix is advancing its pipeline with PRX-115, a PEGylated uricase for uncontrolled gout now in a Phase 2 RELEASE study after a completed Phase 1 trial, and PRX-119, a long-acting DNase I for NETs-related diseases in preclinical development.